NDA

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, August 10, 2022
CONNECT, FDA, Fragile X syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, DiGeorge syndrome, Canaccord Genuity, NDA, Private Securities Litigation Reform Act, FMR1, GLOBE, Methylation, Population, INSPIRE, Growth, LPC, Clinical trial, LLC, Poster, Society, Security (finance), Autism, Marketing, Patient, COVID-19, Company, Twitter, Press release, Infection, FXS, Form 10-K, Skin, Safety, ASD, Research, Cannabidiol, Nasdaq, Fast Track, Royal commission, Time, Annual report, Food, European Commission, Conference, Pharmaceutical industry, Cryptocurrency, Birth control, Jean-François Zygel

DEVON, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights and a pipeline update.

Key Points: 
  • During the second quarter, we were pleased to announce positive topline results from our Phase 2 trial of Zygel in patients with 22q.
  • Research and development expenses were $5.4 million for the second quarter of 2022, including stock-based compensation of $0.5 million.
  • General and administrative expenses were $3.7 million in the second quarter of 2022, including stock-based compensation expense of $0.6 million.
  • Net loss for the second quarter of 2022 was $9.9 million, with basic and diluted loss per share of $(0.24).

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Quanta, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Drug Quality and Security Act, PDUFA, NDA, Melinta Therapeutics, Forward-looking statement, GLOBE, DFC, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Fungemia, Security (finance), Research, Patient, Therapy, COVID-19, SAN, Biotechnology, Partnership, Control, License, NASDAQ, Securities Act of 1933, End-user license agreement, Severe acute respiratory syndrome coronavirus 2, Food, File, Neutralizing antibody, CDTX, Pharmaceutical industry, Vaccine, Tavarua, Janssen

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June30, 2022 and provided an update on its corporate activities and product pipeline.

Key Points: 
  • SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June30, 2022 and provided an update on its corporate activities and product pipeline.
  • We were also pleased to announce a license agreement with Melinta Therapeutics for the U.S. commercialization of rezafungin for up to $460 million.
  • Cidara retains the rights to rezafungin in Japan, while Mundipharma retains the commercial rights to rezafungin outside the U.S. and Japan.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Nausea, Accounting, GLOBE, Triangle Park (Quezon City), Clinical trial, Security (finance), Pain, Marketing, Patient, ASCEND, Dartmouth, Food, Terminology, Migraine, DHE, International Headache Society, Risk, NDA, MBS, Industry, Mayo Clinic College of Medicine and Science, University of Zambia School of Medicine, SAN, Safety, Nasdaq, Magic: The Gathering core sets, 1993–2007, CMC, Geisel School of Medicine, Guideline, COVID-19, Chemistry, Neurology, File, FDA, DC, MedStar Georgetown University Hospital, DRS, Achievement, Plasma, Company, IHS, Research, Dihydroergotamine, Freedom, Pharmaceutical industry, Dietary supplement, Medical device, Science, Cephalalgia

(Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2022 and summarized progress in its STS101 development program.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2022 and summarized progress in its STS101 development program.
  • Satsuma is on track to report topline results from the SUMMIT trial in the fourth quarter of 2022.
  • In May 2022, Satsuma completed clinical and chemistry, manufacturing and controls (CMC) pre-NDA meetings with the FDA for STS101.
  • Research and development expenses were $12.5 million for the second quarter 2022, compared to $8.4 million for the same period of 2021.

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, August 9, 2022
United, ASCO, PARP, NDA, CEO, GLOBE, American Society of Clinical Oncology, Face, Annual general meeting, Schizophrenia, NRDL, Society, Patient, SAN, NMPA, COO, NASDAQ, BLA, Webcast, ADP, Ovarian cancer, CR, Progression-free survival, Medicine, PRIME, III, Niraparib, Fine chemical, Pharmaceutical industry

ET

Key Points: 
  • ET
    SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the second quarter of 2022, along with recent product highlights and corporate updates.
  • We executed well in the second quarter and delivered strong results, said Dr. Samantha Du, Founder, Chairperson and CEO, of Zai Lab.
  • I am thrilled to be joining Zai Lab at such a pivotal time in the companys history, said Josh Smiley, COO of Zai Lab.
  • In July 2022, Zai Lab treated the first patient in Greater China for the global Phase 3 KRYSTAL-12 study of adagrasib in patients with KRASG12C-mutated advanced NSCLC.

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Drug Quality and Security Act, Dermatology, FBI, NDA, Forward-looking statement, GLOBE, Fortress Biotech, Private Securities Litigation Reform Act, Growth, SEC, Atlas Shrugged: Part I, Clinical trial, Securities Exchange Act of 1934, Patent, United States Secretary of Homeland Security, Tobacco Master Settlement Agreement, Rosacea, Research, Annual report, Adjustment, Department, Marketing, Patient, COVID-19, Company, News, NASDAQ, GAAP, Cryptocurrency, Journey, Securities Act of 1933, Investor, Regulation, Communications satellite, Pharmaceutical industry

SCOTTSDALE, Ariz., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter and six months ended June 30, 2022.

Key Points: 
  • ET
    SCOTTSDALE, Ariz., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (Journey Medical or the Company), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter and six months ended June 30, 2022.
  • Net revenues were $18.3 million for the second quarter of 2022, compared to net revenues of $15.3 million for the second quarter of 2021, representing 20% growth versus the second quarter of 2021.
  • Research and development costs were $2.6 million in the second quarter of 2022, compared to $29,000 in the second quarter of 2021, reflecting ongoing clinical trial expenses to develop DFD-29.
  • Journey Medical began receiving royalty payments from Maruho of 10% of net sales of Rapifort in Japan in the second quarter.

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 9, 2022
FDA, MDD, Depression, NDA, GLOBE, Anhedonia, Population, Seizure, Clinical trial, Lists of diseases, Week, MPC, Patient, Retigabine, Adult, Grammatical mood, Icahn School of Medicine at Mount Sinai, Alignment, Magnetic resonance, Safety, FOS, Epilepsy, DBP, Â, OLE, Nasdaq, MADRS, MRI, KCNQ, Pharmaceutical industry, Medical imaging, Xenon

BURNABY, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • BURNABY, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
  • In June 2022, Xenon announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food & Drug Administration (FDA).
  • Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its second quarter results and to provide a corporate update.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

ALYI Announces Building Electric Vehicle Merger and Acquisition Momentum

Retrieved on: 
Tuesday, August 9, 2022
Company, Contract, News, Acquisition, Private Securities Litigation Reform Act, OTC Markets Group, NDA, Attention, GLOBE, Failure, Risk management

ALYI Management today also announces that the company has expanded its merger and acquisition business development initiative to include additional candidates.

Key Points: 
  • ALYI Management today also announces that the company has expanded its merger and acquisition business development initiative to include additional candidates.
  • Our electric motorcycle taxi agreement is developing nicely and getting some very positive attention of late, said ALYI CEO Randell Torno.
  • At the same time, we have also been getting some very encouraging attention surrounding our electric vehicle racing initiative.
  • I believe ALYIs posture is well suited for regaining momentum in the electric vehicle market through the adaptation of our strategy in response to the evolving market conditions, and I anticipate our adaption to include a merger and acquisition aspect.

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, ADHD, SDX, Glycogen storage disease, Ageing, NDA, Endo International, CEO, CNS, GLOBE, Growth, YouTube, Facebook, Benzhydrocodone, Corporate communication, West Virginia University, Niemann–Pick disease, Narcolepsy, Patient, Hydrocodone, Company, Twitter, Acquisition, Central nervous system, NPC, Awareness, Idiopathic hypersomnia, Nasdaq, Medarex, Bristol Myers Squibb, Virginia University, IH, LinkedIn, Paracetamol, Food, KMPH, Pharmaceutical industry, Management

We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.
  • Prior to joining KemPharm, Ms. Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma.
  • Previously, Ms. Ochsner served as Vice President, Investor Relations and Corporate Communications at TherapeuticsMD.
  • Prior to TherapeuticsMD, she was Executive Director, Investor Relations and Corporate Communications at Aralez Pharmaceutical, and, before that, served as Senior Director, Investor Relations and Corporate Communications at Auxilum until its acquisition by Endo International plc for $2.6 billion.

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, NDA, Royalty Pharma, Forward-looking statement, CNS, GLOBE, R, Food and Drug Administration Amendments Act of 2007, Private Securities Litigation Reform Act, Sale, Schizophrenia, Security (finance), Research, Net, Patient, NERV, Company, Central nervous system, Outline, G&A, Interest expense, Neuroscience, Roluperidone, Insurance, Goal, Investor, Nasdaq, Type, New Drug Application, Food, Pharmaceutical industry, Aquaculture, Fine chemical, Lithium

WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2022.

Key Points: 
  • WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2022.
  • Following the Type C meeting, the Company submitted additional data to the FDA to address certain matters discussed at the meeting.
  • At the annual meeting of shareholders held on June 10, 2022 shareholders approved a 1 for 8 reverse stock split of the Companys common stock.
  • Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases.

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, CEO, Visual impairment, TCF Bank Stadium, Day, Ciclosporin, Patient, DED, Therapy, Duane syndrome, Safety, Pathology, Spanish mythology, Pharmacotherapy, ASCRS, Food, Disease, Pharmaceutical industry, Medical imaging

"This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq.

Key Points: 
  • "This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq.
  • "CyclASol is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals.
  • CyclASol is a first-of-a-kind topical treatment of cyclosporine, a potent anti-inflammatory and selective immunomodulatory drug.
  • 2019; 13:2285-2292
    Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease.